Third Melaseq validation study published in PLOS ONE

New research published in PLOS ONE, shows that the Melaseq™ test can (i) be performed using FFPE skin biopsy tissue, (ii)  predict a patient’s length of survival independent to staging and (iii) measures gene activity involved in the regulation of important melanoma immunotherapy targets.